Our services include drug development, medical support, production and distribution of research reagents, and contract research using mass cell culture as a core technology.
- 2015/09/29 Chairman, Dr.Teruaki Sekine had a presentation on the 25th World Congress of Lymphology
- 2015/09/29 Completion of a technology transfer for the activated autologous lymphocyte therapy (Sekine method) to the Grand Zone Intl. Medical Group in Taiwan
- 2015/08/20 September, 2014: LYMPHOTEC Inc. obtained the Exclusive Distribution Rights for Molecular Breast Imaging in APAC region from EVOWORDWIDE Inc.
- 2015/07/16 Announcement of our summer closing period
- 2015/07/01 Lymphotec Inc. signed on a contract for a joint clinical study on activated autologous lymphocyte therapy with the 307th Hospital of Chinese People's Liberation Army and Beijing Longbao Science & Tech･･･
- 2015/06/04 Acquisition of " Certificate for manufacturing of processed product of specific cells" specified in the laws related to the Act regarding Ensuring of Safety of Regenerative Medicine
- 2015/05/22 Dr. Hiroyuki Funamoto, the President and CEO of Lymphotec Inc., delivered lecture in the 14th Annual Meeting of Chinese Society of Cancer Biotherapy held in Beijing, China.